• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinoxalines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinoxalines

Professional Introduction to 9-bromo-6H-indolo[2,3-b]quinoxaline (CAS No. 57743-36-9)

9-bromo-6H-indolo[2,3-b]quinoxaline, identified by the Chemical Abstracts Service Number (CAS No.) 57743-36-9, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of indoloquinoxalines, a structurally complex and biologically relevant scaffold that has been extensively studied for its potential pharmacological activities.

The molecular structure of 9-bromo-6H-indolo[2,3-b]quinoxaline consists of an indole ring fused with a quinoxaline moiety, with a bromine substituent at the 9-position. This unique arrangement of functional groups makes it a versatile intermediate in organic synthesis and a promising candidate for further derivatization to develop novel therapeutic agents. The presence of the bromine atom not only enhances its reactivity but also allows for further chemical modifications, making it a valuable building block in drug discovery programs.

In recent years, there has been growing interest in indoloquinoxalines due to their demonstrated biological activities. Studies have shown that these compounds exhibit a wide range of pharmacological effects, including anti-inflammatory, anticancer, and antimicrobial properties. The indoloquinoxaline scaffold is particularly noted for its ability to interact with various biological targets, making it an attractive scaffold for the development of small-molecule drugs.

One of the most compelling aspects of 9-bromo-6H-indolo[2,3-b]quinoxaline is its potential as an antitumor agent. Research has indicated that indoloquinoxalines can inhibit the growth of cancer cells by targeting key signaling pathways involved in cell proliferation and survival. For instance, studies have demonstrated that certain derivatives of indoloquinoxalines can induce apoptosis in cancer cells by modulating the expression of critical proteins such as Bcl-2 and caspases. This mechanism of action makes 9-bromo-6H-indolo[2,3-b]quinoxaline a promising candidate for further investigation in oncology research.

The brominated derivative 9-bromo-6H-indolo[2,3-b]quinoxaline is particularly interesting because the bromine atom can be readily functionalized through cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These reactions allow for the introduction of diverse substituents at various positions on the indoloquinoxaline core, enabling the synthesis of a library of novel compounds with tailored biological activities. Such chemical versatility makes this compound an invaluable tool for medicinal chemists seeking to develop new therapeutic agents.

In addition to its antitumor potential, 9-bromo-6H-indolo[2,3-b]quinoxaline has also shown promise in other therapeutic areas. For example, preclinical studies have suggested that this compound may have neuroprotective properties, making it a candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The ability of indoloquinoxalines to modulate neurotransmitter systems and protect against oxidative stress has been implicated in their potential therapeutic benefits.

The synthesis of 9-bromo-6H-indolo[2,3-b]quinoxaline involves multi-step organic transformations that highlight its synthetic utility. The key steps typically include the formation of the indole ring followed by its fusion with a quinoxaline moiety. The introduction of the bromine atom at the 9-position is achieved through electrophilic aromatic substitution reactions or metal-catalyzed halogenation processes. These synthetic strategies have been optimized to ensure high yields and purity, making 9-bromo-6H-indolo[2,3-b]quinoxaline readily accessible for further chemical manipulation.

The pharmacological evaluation of 9-bromo-6H-indolo[2,3-b]quinoxaline has been accompanied by extensive computational studies to predict its binding interactions with biological targets. Molecular docking simulations have been used to identify potential binding sites on proteins such as kinases and transcription factors. These studies have provided valuable insights into the mechanism of action of indoloquinoxalines and have guided the design of more potent derivatives.

In conclusion, 9-bromo-6H-indolo[2,3-b]quinoxaline (CAS No. 57743-36-9) is a structurally fascinating and biologically active compound with significant potential in pharmaceutical research. Its unique chemical properties make it an excellent scaffold for developing novel therapeutic agents targeting various diseases, particularly cancer and neurodegenerative disorders. The ongoing research into this compound underscores its importance as a key intermediate in drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)